Vascular smooth muscle cells are responsible for a prothrombotic phenotype of spontaneously hypertensive rat arteries

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 35, Issue 4, 2015, Pages 930-937

  Ait Aissa, Karima ^a,b   Lagrange, Jérémy ^a,b   Mohamadi, Amel ^a,b   Louis, Huguette ^a,b   Houppert, Bénédicte ^a,b   Challande, Pascal ^c,d   Wahl, Denis ^a,b   Lacolley, Patrick ^a,b   Regnault, Véronique ^a,b  

^a INSERM UMR S 1116 University of Lorraine   (France)

^b UNIVERSITÉ DE LORRAINE   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d CNRS   (France)

Author keywords

arteries; rats, inbred SHR; smooth muscle cells; thrombosis

Indexed keywords

GLYCOPROTEIN IB ALPHA; MEMBRANE PHOSPHOLIPID; PROTEIN KINASE B; PROTEINASE ACTIVATED RECEPTOR 1; THROMBIN; THROMBOPLASTIN; VON WILLEBRAND FACTOR; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOLYTIC AGENT; THROMBIN RECEPTOR;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL MODEL; ARTICLE; BLOOD VESSEL WALL; CAROTID ARTERY THROMBOSIS; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; EXPERIMENTAL ARTERY INJURY; FERRIC CHLORIDE-INDUCED THROMBOSIS; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; THORACIC AORTA; THROMBOCYTE COUNT; THROMBOCYTE FREE PLASMA; THROMBOCYTE VOLUME; VASCULAR RING; VASCULAR SMOOTH MUSCLE CELL; WISTAR RAT; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; BLOOD CLOTTING; BLOOD PRESSURE; CELL CULTURE; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; ENDOTHELIUM CELL; GENETICS; MALE; METABOLISM; PATHOPHYSIOLOGY; PHENOTYPE; SMOOTH MUSCLE FIBER; THROMBOCYTE AGGREGATION; THROMBOSIS; TIME; VASCULAR REMODELING; VASCULAR SMOOTH MUSCLE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; AORTA, THORACIC; BLOOD COAGULATION; BLOOD PRESSURE; CELLS, CULTURED; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; FIBRINOLYTIC AGENTS; HYPERTENSION; MALE; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PHENOTYPE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIB-IX COMPLEX; RATS, INBRED SHR; RATS, WISTAR; RECEPTOR, PAR-1; THROMBIN; THROMBOPLASTIN; THROMBOSIS; TIME FACTORS; VASCULAR REMODELING; VON WILLEBRAND FACTOR;

EID: 84930267941     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.115.305377     Document Type: Article

References (33)

1. Esmon CT, Esmon NL. The link between vascular features and thrombosis. Annu Rev Physiol. 2011;73:503-514. doi: 10.1146/ annurev-physiol-012110-142300.
2. Campbell RA, Overmyer KA, Selzman CH, Sheridan BC, Wolberg AS. Contributions of extravascular and intravascular cells to fibrin network formation, structure, and stability. Blood. 2009;114:4886-4896. doi: 10.1182/blood-2009-06-228940.
3. Flynn PD, Byrne CD, Baglin TP, Weissberg PL, Bennett MR. Thrombin generation by apoptotic vascular smooth muscle cells. Blood. 1997;89:4378-4384.
4. Pathak A, Zhao R, Monroe DM, Roberts HR, Sheridan BC, Selzman CH, Stouffer GA. Thrombin generation in vascular tissue. J Thromb Haemost. 2006;4:60-67. doi: 10.1111/j.1538-7836.2005.01630.x.
5. Regnault V, Perret-Guillaume C, Kearney-Schwartz A, Max JP, Labat C, Louis H, Wahl D, Pannier B, Lecompte T, Weryha G, Challande P, Safar ME, Benetos A, Lacolley P. Tissue factor pathway inhibitor: A new link among arterial stiffness, pulse pressure, and coagulation in postmenopausal women. Arterioscler Thromb Vasc Biol. 2011;31:1226-1232. doi: 10.1161/ATVBAHA.110.221911.
6. Arikan E, Sen S. Endothelial damage and hemostatic markers in patients with uncomplicated mild-to-moderate hypertension and relationship with risk factors. Clin Appl Thromb Hemost. 2005;11:147-159.
7. Junker R, Heinrich J, Schulte H, Erren M, Assmann G. Hemostasis in normotensive and hypertensive men: results of the PROCAM study. The prospective cardiovascular Münster study. J Hypertens. 1998;16:917-923.
8. Lip GY, Li-Saw-Hee FL. Does hypertension confer a hypercoagulable state? J Hypertens. 1998;16:913-916.
9. Corseaux D, Ollivier V, Fontaine V, Huisse MG, Philippe M, Louedec L, Vranckx R, Ravanat C, Lanza F, Angles-Cano E, Guillin MC, Michel JB. Hemostasis imbalance in experimental hypertension. Mol Med. 2002;8:169-178.
10. Sawada K, Naiki M, Yago H, Matsushita K, Ohtsuki T, Kitagawa K, Matsumoto M, Hori M. Hypertension associated with reduced plasma thrombomodulin levels and a hypercoagulable state in rats. Clin Exp Hypertens. 2003;25:73-84.
11. Besser M, Baglin C, Luddington R, van Hylckama Vlieg A, Baglin T. High rate of unprovoked recurrent venous thrombosis is associated with high thrombin-generating potential in a prospective cohort study. J Thromb Haemost. 2008;6:1720-1725. doi: 10.1111/j.1538-7836.2008.03117.x.
12. Dargaud Y, Trzeciak MC, Bordet JC, Ninet J, Negrier C. Use of calibrated automated thrombinography +/-thrombomodulin to recognise the prothrombotic phenotype. Thromb Haemost. 2006;96:562-567.
13. Hron G, Kollars M, Binder BR, Eichinger S, Kyrle PA. Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation. JAMA. 2006;296:397-402. doi: 10.1001/ jama.296.4.397.
14. Lecompte T, Wahl D, Perret-Guillaume C, Hemker HC, Lacolley P, Regnault V. Hypercoagulability resulting from opposite effects of lupus anticoagulants is associated strongly with thrombotic risk. Haematologica. 2007;92:714-715.
15. Carcaillon L, Alhenc-Gelas M, Bejot Y, Spaft C, Ducimetière P, Ritchie K, Dartigues JF, Scarabin PY. Increased thrombin generation is associated with acute ischemic stroke but not with coronary heart disease in the elderly: The Three-City cohort study. Arterioscler Thromb Vasc Biol. 2011;31:1445-1451. doi: 10.1161/ATVBAHA.111.223453.
16. Senchenkova EY, Russell J, Esmon CT, Granger DN. Roles of coagulation and fibrinolysis in angiotensin II enhanced microvascular thrombosis. Microcirculation. 2014; 21:401-407.
17. van den Born BJ, Löwenberg EC, van der Hoeven NV, de Laat B, Meijers JC, Levi M, van Montfrans GA. Endothelial dysfunction, platelet activation, thrombogenesis and fibrinolysis in patients with hypertensive crisis. J Hypertens. 2011;29:922-927. doi: 10.1097/ HJH.0b013e328345023d.
18. Lacolley P, Regnault V, Nicoletti A, Li Z, Michel JB. The vascular smooth muscle cell in arterial pathology: A cell that can take on multiple roles. Cardiovasc Res. 2012;95:194-204. doi: 10.1093/cvr/cvs135.
19. Senchenkova EY, Russell J, Kurmaeva E, Ostanin D, Granger DN. Role of T lymphocytes in angiotensin II-mediated microvascular thrombosis. Hypertension. 2011;58:959-965. doi: 10.1161/ HYPERTENSIONAHA.111.173856.
20. Schecter AD, Spirn B, Rossikhina M, Giesen PL, Bogdanov V, Fallon JT, Fisher EA, Schnapp LM, Nemerson Y, Taubman MB. Release of active tissue factor by human arterial smooth muscle cells. Circ Res. 2000;87:126-132.
21. Monroe DM, Hoffman M, Roberts HR. Platelets and thrombin generation. Arterioscler Thromb Vasc Biol. 2002;22:1381-1389.
22. Touyz RM, El Mabrouk M, He G, Wu XH, Schiffrin EL. Mitogen-activated protein/extracellular signal-regulated kinase inhibition attenuates angiotensin II-mediated signaling and contraction in spontaneously hypertensive rat vascular smooth muscle cells. Circ Res. 1999;84:505-515.
23. Morel O, Jesel L, Freyssinet JM, Toti F. Cellular mechanisms underlying the formation of circulating microparticles. Arterioscler Thromb Vasc Biol. 2011;31:15-26. doi: 10.1161/ATVBAHA.109.200956.
24. Crawley JT, Lane DA. The haemostatic role of tissue factor pathway inhibitor. Arterioscler Thromb Vasc Biol. 2008;28:233-242. doi: 10.1161/ ATVBAHA.107.141606.
25. Clozel M, Kuhn H, Hefti F, Baumgartner HR. Endothelial dysfunction and subendothelial monocyte macrophages in hypertension. Effect of angiotensin converting enzyme inhibition. Hypertension. 1991;18:132-141.
26. Intengan HD, Thibault G, Li JS, Schiffrin EL. Resistance artery mechanics, structure, and extracellular components in spontaneously hypertensive rats: effects of angiotensin receptor antagonism and converting enzyme inhibition. Circulation. 1999;100:2267-2275.
27. Stouffer GA, Smyth SS. Effects of thrombin on interactions between beta3-integrins and extracellular matrix in platelets and vascular cells. Arterioscler Thromb Vasc Biol. 2003;23:1971-1978. doi: 10.1161/01. ATV.0000093470.51580.0F.
28. Mao X, Said R, Louis H, Max JP, Bourhim M, Challande P, Wahl D, Li Z, Regnault V, Lacolley P. Cyclic stretch-induced thrombin generation by rat vascular smooth muscle cells is mediated by the integrin αvβ3 pathway. Cardiovasc Res. 2012;96:513-523. doi: 10.1093/cvr/cvs274.
29. Borissoff JI, Spronk HM, Heeneman S, ten Cate H. Is thrombin a key player in the 'coagulation-atherogenesis' maze? Cardiovasc Res. 2009;82:392-403. doi: 10.1093/cvr/cvp066.
30. Mahajan SG, Fender AC, Meyer-Kirchrath J, Kurt M, Barth M, Sagban TA, Fischer JW, Schrör K, Hohlfeld T, Rauch BH. A novel function of FoxO transcription factors in thrombin-stimulated vascular smooth muscle cell proliferation. Thromb Haemost. 2012;108:148-158. doi: 10.1160/ TH11-11-0756.
31. Jackson SP. Arterial thrombosis-insidious, unpredictable and deadly. Nat Med. 2011;17:1423-1436. doi: 10.1038/nm.2515.
32. Le Behot A, Gauberti M, Martinez De Lizarrondo S, Montagne A, Lemarchand E, Repesse Y, Guillou S, Denis CV, Maubert E, Orset C, Vivien D. GpIbα-VWF blockade restores vessel patency by dissolving platelet aggregates formed under very high shear rate in mice. Blood. 2014;123:3354-3363. doi: 10.1182/blood-2013-12-543074.
33. Stalker TJ, Traxler EA, Wu J, Wannemacher KM, Cermignano SL, Voronov R, Diamond SL, Brass LF. Hierarchical organization in the hemostatic response and its relationship to the platelet-signaling network. Blood. 2013;121:1875-1885. doi: 10.1182/blood-2012-09-457739.